|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNPEP |
Gene summary for DNPEP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNPEP | Gene ID | 23549 |
| Gene name | aspartyl aminopeptidase | |
| Gene Alias | ASPEP | |
| Cytomap | 2q35 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | B7Z7F0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23549 | DNPEP | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.93e-02 | 2.45e-01 | -0.1808 |
| 23549 | DNPEP | HTA11_78_2000001011 | Human | Colorectum | AD | 1.55e-04 | 3.23e-01 | -0.1088 |
| 23549 | DNPEP | HTA11_347_2000001011 | Human | Colorectum | AD | 8.03e-07 | 2.65e-01 | -0.1954 |
| 23549 | DNPEP | HTA11_83_2000001011 | Human | Colorectum | SER | 1.90e-03 | 3.22e-01 | -0.1526 |
| 23549 | DNPEP | HTA11_696_2000001011 | Human | Colorectum | AD | 8.61e-03 | 3.23e-01 | -0.1464 |
| 23549 | DNPEP | HTA11_866_3004761011 | Human | Colorectum | AD | 2.52e-05 | 3.09e-01 | 0.096 |
| 23549 | DNPEP | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.79e-03 | 3.83e-01 | 0.3859 |
| 23549 | DNPEP | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.76e-09 | 5.04e-01 | 0.3005 |
| 23549 | DNPEP | A015-C-203 | Human | Colorectum | FAP | 1.61e-04 | 5.30e-02 | -0.1294 |
| 23549 | DNPEP | A001-C-108 | Human | Colorectum | FAP | 8.96e-04 | -9.94e-02 | -0.0272 |
| 23549 | DNPEP | A015-C-104 | Human | Colorectum | FAP | 3.22e-05 | -7.40e-02 | -0.1899 |
| 23549 | DNPEP | A002-C-016 | Human | Colorectum | FAP | 1.45e-04 | -1.11e-01 | 0.0521 |
| 23549 | DNPEP | A002-C-116 | Human | Colorectum | FAP | 3.79e-05 | -1.35e-01 | -0.0452 |
| 23549 | DNPEP | LZE4T | Human | Esophagus | ESCC | 7.30e-06 | 2.34e-01 | 0.0811 |
| 23549 | DNPEP | LZE7T | Human | Esophagus | ESCC | 2.01e-08 | 2.16e-01 | 0.0667 |
| 23549 | DNPEP | LZE8T | Human | Esophagus | ESCC | 2.64e-10 | 3.13e-01 | 0.067 |
| 23549 | DNPEP | LZE20T | Human | Esophagus | ESCC | 2.63e-05 | 2.40e-01 | 0.0662 |
| 23549 | DNPEP | LZE22T | Human | Esophagus | ESCC | 1.57e-03 | 5.06e-01 | 0.068 |
| 23549 | DNPEP | LZE24T | Human | Esophagus | ESCC | 5.82e-30 | 8.34e-01 | 0.0596 |
| 23549 | DNPEP | LZE21T | Human | Esophagus | ESCC | 5.39e-04 | 2.85e-01 | 0.0655 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNPEP | SNV | Missense_Mutation | novel | c.559N>T | p.Ile187Phe | p.I187F | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A3KC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| DNPEP | SNV | Missense_Mutation | novel | c.214N>A | p.Glu72Lys | p.E72K | protein_coding | tolerated(0.06) | benign(0.056) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DNPEP | SNV | Missense_Mutation | c.278N>A | p.Ala93Asp | p.A93D | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| DNPEP | SNV | Missense_Mutation | novel | c.590T>G | p.Phe197Cys | p.F197C | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-AB28-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| DNPEP | SNV | Missense_Mutation | c.958G>C | p.Glu320Gln | p.E320Q | protein_coding | deleterious(0.01) | probably_damaging(0.957) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| DNPEP | SNV | Missense_Mutation | novel | c.341A>G | p.Asp114Gly | p.D114G | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| DNPEP | SNV | Missense_Mutation | novel | c.828N>G | p.Ile276Met | p.I276M | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| DNPEP | SNV | Missense_Mutation | rs781324438 | c.1168G>A | p.Val390Met | p.V390M | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| DNPEP | SNV | Missense_Mutation | c.583G>A | p.Glu195Lys | p.E195K | protein_coding | tolerated(0.15) | possibly_damaging(0.703) | TCGA-AA-3680-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | PD | ||
| DNPEP | SNV | Missense_Mutation | c.1196N>T | p.Tyr399Phe | p.Y399F | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 23549 | DNPEP | ENZYME, NEUTRAL ZINC METALLOPEPTIDASE, DRUGGABLE GENOME, PROTEASE | inhibitor | 252166877 | ||
| 23549 | DNPEP | ENZYME, NEUTRAL ZINC METALLOPEPTIDASE, DRUGGABLE GENOME, PROTEASE | QGC-001 | |||
| 23549 | DNPEP | ENZYME, NEUTRAL ZINC METALLOPEPTIDASE, DRUGGABLE GENOME, PROTEASE | inhibitor | CHEMBL2103847 | TOSEDOSTAT |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |